Early vs delayed treatment for high-risk CLL: cost study
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares early treatment versus delaying treatment in newly diagnosed people with high-risk CLL/SLL who feel well. It mainly looks at the overall “costs and value” of each approach and asks patients to complete short health and quality-of-life questionnaires.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must first qualify for the main CLC3/S1925 treatment study plan.
- You must be able to and willing to sign a consent form before joining.
- You must be willing to complete health and quality-of-life questionnaires in English or French.
- You must be available for ongoing visits and follow-up so the team can track treatment and side effects.
- You should be able to complete baseline paperwork and questionnaires within the required time window.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
This observational study looks at the order of treatments given to people with chronic lymphocytic leukemia (CLL) who took part in certain first-line studies run by the German CLL Study Group. It aims to learn how different treatment sequences affect overall survival over time.
This trial tests TQB3909 tablets in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or did not respond to prior treatment. The goal is to see if the drug is safe and can shrink the cancer or improve control of the disease.
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
This British Columbia study looks at how well different cancer treatments work in real life when doctors aren't sure which option is best. You and your doctor would choose a treatment, and researchers will track your results to help others.
This study collects evidence on personalized (“targeted”) cancer treatments for adults with rare cancers or rare tumor changes. If you may qualify, it may help make these treatments more widely available in the future by studying how well they work and how patients feel.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.